These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27834470)

  • 41. [Diagnosis of prostate cancer with PSA < or =4.0 microg/L].
    Liu X; Tang J; Fei X; Li QY
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):234-8. PubMed ID: 24738460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early diagnosis of prostate cancer in the Western Cape.
    Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
    S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH
    Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.
    Karakiewicz PI; Benayoun S; Kattan MW; Perrotte P; Valiquette L; Scardino PT; Cagiannos I; Heinzer H; Tanguay S; Aprikian AG; Huland H; Graefen M
    J Urol; 2005 Jun; 173(6):1930-4. PubMed ID: 15879784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
    Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
    Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
    Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
    Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.
    Al-Azab R; Toi A; Lockwood G; Kulkarni GS; Fleshner N
    Urology; 2007 Jan; 69(1):103-7. PubMed ID: 17270628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Relation of age and prostatic volume to cancer detection in prostatic biopsies from patients with non-suspect rectal palpation].
    Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Subira Ríos D; Castaño González I; Moralejo Gárate M; Martínez Salamanca JI; Cabello Benavente R
    Arch Esp Urol; 2003 May; 56(4):359-66. PubMed ID: 12830608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.
    Borden LS; Wright JL; Kim J; Latchamsetty K; Porter CR
    BJU Int; 2007 Mar; 99(3):559-63. PubMed ID: 17155976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is it effective to perform two more prostate biopsies according to prostate-specific antigen level and prostate volume in detecting prostate cancer? Prospective study of 10-core and 12-core prostate biopsy.
    Yoon BI; Shin TS; Cho HJ; Hong SH; Lee JY; Hwang TK; Kim SW
    Urol J; 2012; 9(2):491-7. PubMed ID: 22641493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
    Oranusi CK; Ugezu AI; Nwofor A
    Niger J Clin Pract; 2012; 15(1):48-50. PubMed ID: 22437089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
    Scattoni V; Raber M; Abdollah F; Roscigno M; Dehò F; Angiolilli D; Maccagnano C; Gallina A; Capitanio U; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Eur Urol; 2010 Jan; 57(1):1-8. PubMed ID: 19720449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indonesian prostate cancer risk calculator (IPCRC): an application for predicting prostate cancer risk (a multicenter study).
    Yuri P; Wangge G; Abshari F; Satjakoesoemah AI; Perdana NR; Wijaya CD; Tansol C; Tigor A; Safriadi F; Kadar DD; Warli SM; Rochadi S; Danarto ; Hakim L; Djatisoesanto W; Hardjowijoto S; Mochtar CA; Umbas R; Hamid AR
    Acta Med Indones; 2015 Apr; 47(2):95-103. PubMed ID: 26260551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.